Special Issue

Bacteriophages: An Inspiration for the Development of New Antimicrobial and Antibiofilm Agents

Message from the Guest Editor

In the context of the current antimicrobial resistance crisis, the development of novel and revamped strategies to fight pathogenic bacteria is paramount. Once discarded as flawed compared to antibiotics, the use of bacterial viruses as sophisticated, high precision weapons is again considered a viable option. Bacteriophages also serve as inspiration for the design of new antimicrobial compounds. For instance, phage-derived lytic proteins, also called enzybiotics, while hardly selecting any resistant mutantsThis special issue aims to provide an update on phage-based antimicrobials, including, but not limited to, their efficacy and safety, the design of new protocols to ensure therapeutic success, their combination with other antibacterial agents, their use against bacterial biofilms, and the potential development of bacterial resistance.

Guest Editor

Dr. Lucía Fernández

Department of Technology and Biotechnology of Dairy Products, Dairy Research Institute of Asturias (IPLA-CSIC), 33300 Villaviciosa, Spain

Deadline for manuscript submissions

closed (31 January 2021)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/37232

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI